Literature DB >> 33643919

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment.

Xiuzhen Zhang1, Tong Meng2, Shuaishuai Cui1, Ling Feng1, Dongwu Liu1,3, Qiuxiang Pang1, Ping Wang1.   

Abstract

Ubiquitination, a crucial post-translation modification, regulates the localization and stability of the substrate proteins including nonhistone proteins. The ubiquitin-proteasome system (UPS) on nonhistone proteins plays a critical role in many cellular processes such as DNA repair, transcription, signal transduction, and apoptosis. Its dysregulation induces various diseases including cancer, and the identification of this process may provide potential therapeutic targets for cancer treatment. In this review, we summarize the regulatory roles of key UPS members on major nonhistone substrates in cancer-related processes, such as cell cycle, cell proliferation, apoptosis, DNA damage repair, inflammation, and T cell dysfunction in cancer. In addition, we also highlight novel therapeutic interventions targeting the UPS members (E1s, E2s, E3s, proteasomes, and deubiquitinating enzymes). Furthermore, we discuss the application of proteolysis-targeting chimeras (PROTACs) technology as a novel anticancer therapeutic strategy in modulating protein target levels with the aid of UPS.
Copyright © 2021 Zhang, Meng, Cui, Feng, Liu, Pang and Wang.

Entities:  

Keywords:  E3 ligase; cancer; deubiquitinase; nonhistone protein; proteolysis-targeting chimeras; ubiquitination

Year:  2021        PMID: 33643919      PMCID: PMC7905169          DOI: 10.3389/fonc.2020.621294

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  201 in total

1.  Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.

Authors:  Hui-Lin Huang; Heng-You Weng; Lu-Qin Wang; Chun-Hong Yu; Qiao-Juan Huang; Pan-Pan Zhao; Jun-Zhi Wen; Hui Zhou; Liang-Hu Qu
Journal:  Mol Cancer Ther       Date:  2012-03-02       Impact factor: 6.261

Review 2.  E3 ubiquitin ligases in cancer and implications for therapies.

Authors:  Dong Wang; Leina Ma; Bin Wang; Jia Liu; Wenyi Wei
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

3.  Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Authors:  Philipp Holzer; Keiichi Masuya; Pascal Furet; Joerg Kallen; Therese Valat-Stachyra; Stéphane Ferretti; Joerg Berghausen; Michèle Bouisset-Leonard; Nicole Buschmann; Carole Pissot-Soldermann; Caroline Rynn; Stephan Ruetz; Stefan Stutz; Patrick Chène; Sébastien Jeay; Francois Gessier
Journal:  J Med Chem       Date:  2015-08-05       Impact factor: 7.446

4.  Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Authors:  Thomas Leonard Joseph; Arumugam Madhumalar; Christopher J Brown; David P Lane; Chandra S Verma
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

5.  NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.

Authors:  Go Kuratomi; Akiyoshi Komuro; Kouichiro Goto; Masahiko Shinozaki; Keiji Miyazawa; Kohei Miyazono; Takeshi Imamura
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

6.  Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2.

Authors:  Min Liang; Yao-Yun Liang; Katharine Wrighton; Dana Ungermannova; Xiao-Ping Wang; F Charles Brunicardi; Xuedong Liu; Xin-Hua Feng; Xia Lin
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 7.  Regulation of NF-κB by ubiquitination.

Authors:  Jueqi Chen; Zhijian J Chen
Journal:  Curr Opin Immunol       Date:  2013-01-08       Impact factor: 7.486

8.  USP10 regulates p53 localization and stability by deubiquitinating p53.

Authors:  Jian Yuan; Kuntian Luo; Lizhi Zhang; John C Cheville; Zhenkun Lou
Journal:  Cell       Date:  2010-01-21       Impact factor: 41.582

9.  Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Authors:  Yong S Chang; Bradford Graves; Vincent Guerlavais; Christian Tovar; Kathryn Packman; Kwong-Him To; Karen A Olson; Kamala Kesavan; Pranoti Gangurde; Aditi Mukherjee; Theresa Baker; Krzysztof Darlak; Carl Elkin; Zoran Filipovic; Farooq Z Qureshi; Hongliang Cai; Pamela Berry; Eric Feyfant; Xiangguo E Shi; James Horstick; D Allen Annis; Anthony M Manning; Nader Fotouhi; Huw Nash; Lyubomir T Vassilev; Tomi K Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-14       Impact factor: 11.205

Review 10.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29
View more
  2 in total

Review 1.  Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review).

Authors:  Xiuzhen Zhang; Tong Meng; Shuaishuai Cui; Dongwu Liu; Qiuxiang Pang; Ping Wang
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

Review 2.  Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.

Authors:  Alberto Juan; María Del Mar Noblejas-López; María Arenas-Moreira; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Front Cell Dev Biol       Date:  2022-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.